Xlear Challenges FTC Oversight on Health Claims
In a bold legal move, Xlear, a company known for its saline nasal spray, is suing the Federal Trade Commission (FTC) after being accused of spreading misleading covid-19 prevention claims. At the height of the pandemic, Xlear marketed its spray as a scientifically backed defense against the virus—despite lacking conclusive medical evidence. The FTC, which regulates deceptive advertising, sued Xlear in 2021, alleging it exaggerated scientific findings. Now, years later, Xlear wants the courts to limit the FTC’s authority in regulating health claims, potentially reshaping how wellness products are advertised in the U.S.
FTC Health Claims Lawsuit Sparks Industry Debate
The FTC health claims lawsuit against Xlear stemmed from ads suggesting the nasal spray could block covid-19 infection, citing limited studies. But according to the FTC, these claims were not supported by rigorous scientific consensus. While the Trump-era Department of Justice asked to drop the suit in early 2025 without explanation, Xlear wasn’t satisfied. Instead of celebrating a legal win, the company launched a counterattack, filing its own lawsuit that questions the FTC’s ability to regulate claims about health products altogether. The case could create ripple effects across the supplement, natural remedy, and wellness markets.
Xlear’s Legal Strategy Could Shift Regulatory Power
What makes Xlear’s case especially controversial is its timing. The federal approach to public health and agency authority has already been destabilized by recent political changes. Health Secretary Robert F. Kennedy Jr. recently overhauled key CDC advisory committees, raising questions about how science is interpreted at the federal level. In that climate, Xlear’s lawsuit could gain unexpected traction by arguing that agencies like the FTC should face tighter scrutiny before they challenge product marketing claims—especially those related to health.
Why the Outcome Matters for Consumers and Regulators
At its core, the FTC health claims lawsuit is about trust—both in the products consumers use and in the institutions designed to protect them. If Xlear succeeds, the FTC could face higher barriers when policing unproven health-related marketing. That might open the door for more questionable wellness claims to spread unchecked. On the other hand, the case raises legitimate legal questions about agency overreach and due process. As the legal battle unfolds, it will serve as a critical test for the balance between consumer protection and corporate free speech in the health product industry.
Comment